Leksell Gamma Knife® Perfexion™ is the latest and most advanced solution on the market for non-invasive treatment of brain disorders. This new generation Leksell Gamma Knife is fully automated and has the ability to treat patients with multiple brain metastases in much shorter times compared to other technologies.
Gamma Knife® surgery is used to manage numerous neurosurgical conditions, including brain tumors such as metastatic cancer, as well as vascular malformations and certain functional disorders. This unmatched method provides pinpoint accuracy, is highly efficient and produces outstanding results. Patients benefit from fast, painless treatment, often conducted in an outpatient surgical setting without the need for general anesthesia or even convalescence. To date, over 500,000 patients world wide have undergone Gamma Knife surgery.
“Leksell Gamma Knife Perfexion technology represents a major advance in brain radiosurgery,” says Olof Sandén, Executive Vice President, Elekta Europe, Africa & Latin America. “It also offers enormous opportunities to treat lesions all over the brain in a single treatment, while also ensuring excellent patient comfort” he says. “We are pleased to see the considerable interest in the new system, among both old and new users. Leksell Gamma Knife Perfexion was introduced two years ago and today we have already installed around 30 systems around the world”, Olof Sandén says.
For further information, please contact:
Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com
About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
